Compare AAT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | ANAB |
|---|---|---|
| Founded | 1967 | 2005 |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2010 | 2015 |
| Metric | AAT | ANAB |
|---|---|---|
| Price | $19.48 | $54.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $20.00 | ★ $62.20 |
| AVG Volume (30 Days) | ★ 491.6K | 409.7K |
| Earning Date | 05-05-2026 | 04-05-2026 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $436,204,000.00 | $91,280,000.00 |
| Revenue This Year | $6.32 | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | N/A | ★ 432.03 |
| 52 Week Low | $16.69 | $14.01 |
| 52 Week High | $22.79 | $57.65 |
| Indicator | AAT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 61.02 |
| Support Level | $17.80 | $53.00 |
| Resistance Level | $19.32 | $56.28 |
| Average True Range (ATR) | 0.45 | 3.49 |
| MACD | 0.08 | 0.37 |
| Stochastic Oscillator | 85.50 | 70.80 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).